The Summary
This systematic review analyzed 38 randomized controlled trials with 25,816 adults with overweight or obesity without diabetes. Placebo-adjusted weight reductions reached up to 14.8% for injectable semaglutide, 14.3% for oral semaglutide, and 19.0% for tirzepatide. Emerging multiagonist medications achieved even greater results, with retatrutide and amycretin yielding up to 22.1% and 23.9% weight loss, respectively. Gastrointestinal side effects occurred in 76.0% of treated participants versus 40.1% on placebo, but serious adverse events were rare and treatment discontinuations remained generally low.
Why this is interesting
GLP-1 medications like semaglutide transformed modern medicine, but new drug candidates are raising the bar. These findings demonstrate that next-generation multi-receptor agonists, alongside convenient oral formulations, can achieve up to 24% reductions in body weight—approaching levels historically seen only with bariatric surgery. For patients, this points to an expanding array of needle-free and more potent alternatives for chronic health management. While digestive side effects like nausea remain common, serious safety risks remain rare, reassuring patients and providers about the safety of this fast-evolving drug class.